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Extracellular vesicles (EVs) are nanoscale size vesicles secreted by cells and are
important mediators of intercellular communication and genetic exchange. Exosomes,
EVs generated in endosomal multivesicular bodies, have been the focus of numerous
publications as they have emerged as clinically valuable markers of disease states.
Exosomes have been mostly studied from conditioned culture media and body fluids,
with the difficulty of isolating exosomes from tissues having delayed their study in vivo.
The implementation of a method designed to isolate exosomes from tissues, however,
has yielded the first insights into characteristics of exosomes in the brain. It has been
observed that brain exosomes from murine models of neurodegenerative diseases and
human postmortem brains tend to mirror the protein content of the cells of origin,
and interestingly, they are enriched with toxic proteins. Whether this enrichment with
neurotoxic proteins is beneficial by relieving neurons of accumulated toxic material or
detrimental to the brain by propagating pathogenicity throughout the brain remains to be
answered. Here is summarized the first group of studies describing exosomes isolated
from brain, results that demonstrate that exosomes in vivo reflect complex multicellular
pathogenic processes in neurodegenerative disorders and the brain’s response to injury
and damage.
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INTRODUCTION
Extracellular vesicles (EVs) are phospholipid bilayer membrane-enclosed vesicles that contain
lipids, proteins, and RNA (mRNA and miRNA), secreted by cells into tissue extracellular spaces
and biological fluids, and in vitro, into cultured conditioned media. in vitro studies have shown
that cells release subpopulations of EVs with distinct molecular and biological properties (Lai
et al., 2016; Willms et al., 2016), with the various species of EVs having different intracellular
sites of origin (reviewed in van der Pol et al., 2012; Kowal et al., 2014; Kalra et al., 2016). Plasma
membrane-derived microvesicles have a diameter of 100–1000 nm. While these microvesicles
are continuously shed from all viable cells, their release from the cell can be triggered under
specific pathological conditions (Borroto-Escuela et al., 2015). The EVs species most extensively
studied is the exosome, 20–100 nm vesicles formed by the invagination of the membrane of late
endosome/multivesicular body (MVB) around cytoplasmic materials (reviewed in Kreimer et al.,
2015; van der Pol et al., 2015). Mature exosomes remain inside the lumen of the MVB until
they are secreted into the extracellular space when the MVB fuses with the plasma membrane
(Stoorvogel et al., 2002). Secreted exosomes are taken-up by target cells, with the exosomal content
delivered into the recipient cell (Fevrier and Raposo, 2004). Secreted exosomes were first isolated
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from the conditioned medium of immature sheep reticulocytes
(Johnstone et al., 1987). Since then, in vitro studies have shown
that exosomes are secreted by various cell types (Simpson et al.,
2008), including neurons and astrocytes (Faure et al., 2006).
Rat and mouse cortical neurons secrete exosomes in culture
that have the typical features of size, density, and saponin
sensitivity of exosomes secreted by other cells (Faure et al.,
2006). Using proteomic methods, it was also shown that these
exosomes resemble exosomes isolated from other non-neuronal
cell types, containing typical exosomal markers such as Alix,
flotillin, and tumor susceptibility gene-101 (TSG101), but also
contain neuron-specific components (Faure et al., 2006).
Exosomes secretion was originally described as a
complementary process to the lysosomal and proteosomal
degradative pathways for shedding of obsolete membrane and
cytosolic proteins (Johnstone et al., 1987). The identification
of neuron-specific components associated with exosomes
isolated from media conditioned by cultured cells (Faure et al.,
2006) suggested that secreted exosomes have roles in cell
signaling functions (Record et al., 2011) by shuttling cargo
between cells and tissues (Smalheiser, 2007), contributing to the
regulation of neurotransmitter receptor levels at the synapse, the
production and turnover of myelin membranes proteins, and
participating in the progression of neurodegenerative diseases
(Gould et al., 2003; Vella et al., 2008; Izquierdo-Useros et al.,
2011). A pathogenic function of exosomes has been additionally
proposed, suggesting that exosomes can transfer pathogens
between cells. One such pathogen that exploits this pathway is
the prion protein (PrP), the infectious particle responsible for
transmissible neurodegenerative diseases such as Creutzfeldt-
Jakob disease of humans and bovine spongiform encephalopathy
of cattle (Vella et al., 2008). α-synuclein, involved in the
pathogenesis of Parkinson’s disease is secreted in a calcium-
dependent manner by exosomes (Emmanouilidou et al., 2010).
A pathogenic role for exosomes was also proposed for amyloid
β (Aβ) (Rajendran et al., 2006) and for phosphorylated tau
(Saman et al., 2012), both deposited in the brain of Alzheimer’s
disease (AD) patients. These data suggest that exosomes may
contribute to intercellular membrane exchange and the spread
of aggregation-prone proteins throughout the brain. However,
exosomes may have a protective function by relieving the cells
from toxic accumulation of peptides such as PrP, α-synuclein, as
well as Aβ and the amyloid β precursor protein (APP) carboxyl
terminal fragments (APP-CTFs) that accumulate intracellularly
and disrupt the normal function of the endosomal-lysosomal
system to degrade proteins. Thus, I have hypothesized that
exosomes secretion plays a pleiotropic role in the brain, both
beneficial to the cell by discarding accumulated, toxic material,
but also potentially harmful to the brain by contributing to
the extracellular build up and transport between cells of toxic
material.
Isolating exosomes from in vitro sources has provided data
on the level and content of exosomes secretion by specific
cell types but cannot provide information on the in vivo
physiological effect on exosomes secretion by multiple cell types
under normal, developmental as well as pathological conditions.
While exosomes isolated from cerebrospinal fluid (CSF) are
enriched in proteins derived from brain, including neuronal
and microglia markers, the origin of exosomes in the CSF is
not strictly from the brain (reviewed in Vella et al., 2016).
Although CSF-derived exosomes can serve as biomarkers for
brain disease when changes in specific proteins, lipids, or RNA
are detected, there is a need to investigate the changes that
occur in the brain environment leading to disease initiation and
progression. Moreover, given that in most neurodegenerative
disorders the primary changes occur in specific localization
within the brain, followed by propagation of pathology into well-
defined brain regions, it is likely that the levels of secretion and
cargo compositions of exosomes are not homogeneous among
various brain regions. Understanding this diversity requires the
investigation of exosomes content not only in the brain as a whole
but also in distinct brain regions.
Understanding exosomes-based signaling in the brain will
likely advance knowledge of neurobiology in the non-affected
brain, under normal conditions, in addition to understanding
disease-related roles of exosomes. The first protocol to isolate
exosomes from brain tissues was developed by Perez-Gonzalez
et al. (2012), and a second method has been described, a
protein organic solvent precipitationmethod (Gallart-Palau et al.,
2016). Both methods efficiently isolate brain tissue exosomes
in amounts sufficient to characterize exosomes by multiple
technologies, including “omics” (Gallart-Palau et al., 2016 and
Perez-Gonzalez and Levy, personal communication). Given
the recent development of such methodology, the number of
publications of studies describing brain exosomes is limited.
Nevertheless, these studies highlight the unique data that can be
obtained by directly isolating and characterizing brain exosomes.
This review describes the data obtained from exosomes isolated
from brain tissue of patients with neurodegenerative disorders,
data that could not be obtained from exosomes isolated from
body fluids or conditioned media.
METHOD TO ISOLATE EXOSOMES FROM
BRAIN TISSUE
While exosomes have been successfully isolated from cell
culture media and body fluids including CSF, blood, saliva,
and urine (Lakkaraju and Rodriguez-Boulan, 2008; Simpson
et al., 2008), similar isolation methods for brain exosomes
yielded vesicles contaminated with cellular debris, as observed by
electron microscopy and Western blot analysis with antibodies
to intracellular compartments. We have successfully isolated
exosomes-enriched EVs from brain that are not contaminated
by cellular debris or intracellular vesicles (Perez-Gonzalez
et al., 2012). While this protocol requires rigor and precise
performance and we have found that deviation from some of the
technique’s details can prevent success, several researchers have
successfully isolated brain exosomes following our published
protocol; their findings are described below. This protocol
starts with a gentle dissociation of the tissue to free the brain
extracellular space, keeping the cells intact, the same method
we have been using for the isolation of intact neurons, glia,
smooth muscle cells, and endothelial cells from brain for culture
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(Jung and Levy, 2005). The brain tissue is not homogenized,
but gently disassociated. Unfortunately, in some manuscripts
the method has been described as a “homogenization” although
the actual technique described involved the gentle dissociation
as described in Perez-Gonzalez et al. (2012). After a low-speed
centrifugation to discard large debris, the sample is sequentially
filtered through 0.4 and 0.2 µm filters to further eliminate
remaining debris and vesicles larger than 200 nm, followed by
low-speed centrifugations and ultracentrifugations (see Figure 1
and Perez-Gonzalez et al., 2012 for details of our protocol).
Electronmicroscopy of brain EVs demonstrated that this method
yields EVs preparations free of debris and subcellular organelles,
such as the nucleus, endoplasmic reticulum, mitochondria,
and Golgi (Perez-Gonzalez et al., 2012). Western blot analysis
demonstrated that the EVs did not contain proteins of
intracellular compartments such as endoplasmic reticulum or
Golgi, but contained markers of exosomes, indicating the purity
of the samples. This procedure yields vesicles that match in shape,
size, density, and protein content exosomes previously isolated
from body fluids or from the conditioned media of various types
of cell cultures (Thery et al., 2006; Simpson et al., 2008). As
was previously shown for human urine (Zhou et al., 2006),
CSF (Harrington et al., 2009), and plasma (Grant et al., 2011),
intact exosomes can be isolated from frozen brain tissues as well.
Electron microscopy revealed no difference between exosomes
isolated from human brain tissues frozen for several years at
−80◦C, mouse brains frozen for long periods of time at −80◦C,
and freshly isolated mouse brains.
Each of the studies that have used this isolation method,
described below, employed Western blotting and immuno-EM
with exosomes-specific antibodies to identify exosomes within
the isolated EVs. These include antibodies to proteins such as the
TSG101, required for endosomal sorting complex required for
transport (ESCRT) recruitment to endosomal membranes during
the process of exosomes generation (de Gassart et al., 2004),
multiple rab GTPase, key regulators of intracellular membrane
trafficking, including rab27a and rab27b that function in MVB
docking at the plasma membrane (Ostrowski et al., 2010), and
rab35, which regulates exosomes secretion (Hsu et al., 2010). The
endosomal origin of exosomes is supported by the identification
of rab5 isoforms (rab5a, rab5b, rab5c), proteins essential for
the fusion of early endosomes and regulation of endocytosis,
in exosomes (Agola et al., 2011; Pfeffer, 2013). Brain exosomes
also contained various tetraspanin proteins, such as CD9, CD63,
CD81, abundantly present in the endosomal-lysosomal pathway
where they are enriched on the intraluminal vesicles and
extensively used asmarkers of exosomes (Abache et al., 2007; Pols
and Klumperman, 2009; Jorgensen et al., 2013).
EXOSOMES ISOLATED FROM BRAIN
PROVIDE UNIQUE DATA ON THE ROLE OF
EXOSOMES IN NEURODEGENERATIVE
DISORDERS
Multiple studies have shown that the levels and composition of
exosomes are affected by, and contribute to, disease progression
(Kreimer et al., 2015) although the mechanisms are poorly
understood (Urbanelli et al., 2013). Changes in exosomes
generation, secretion, uptake, or clearance, manifested by
changes in the number of exosomes in the brain extracellular
space, may have either protective or pathogenic effect. Given
that exosomes contain amyloidogenic and toxic material,
exosomes release can serve a neuroprotective function through
the elimination of neurotoxic molecules that cause neuronal
endosomal-autophagic-lysosomal abnormalities and functional
sequelae, including memory loss. Recent studies have shown
that exosomes uptake by microglia is more efficient than by
neurons (Fitzner et al., 2011; Yuyama et al., 2012), suggesting
that exosomes release may have a neuroprotective function by
allowing a neuron to shed deleterious components that are
then targeted to and degraded by non-neuronal cells (Joshi
et al., 2015). Unfortunately, the elimination of cytotoxic material
associated with exosomes by neurons, if not efficiently degraded,
may lead to a propagation of toxicity and pathology in the brain,
as has been suggested for prion diseases (Vella et al., 2008). The
direct isolation of exosomes from the tissue has the advantage of
revealing in vivo processes in the normal brain as well as changes
that occur within the environment of the brain during normal
aging or those leading to disease. While regional analyses can be
performed, such studies provide limited information on the cell
of origin of the exosomes or the mechanisms leading to altered
exosomes levels in the brain. To this end, in vivo studies often
need to be accompanied by in vitro studies in which exosomes
are isolated from specific cell types, such as neurons, astrocytes,
and microglia. This section provides published examples of
the unique data obtained from exosomes isolated from brain
tissue. While the extent of published studies to date remains
limited, these studies and their findings encourage the use of this
FIGURE 1 | Brain exosome isolation experimental flow chart. The steps of the experimental procedure designed to isolate and purify brain exosomes are
described.
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methodology to further delineate the roles of exosomes secretion,
uptake, and signaling in the normal and diseased brain.
The Normal Brain
Isolation of exosomes from brain can serve as a confirmation
that processes observed in the in vitro model also occur
in vivo in the brain. For example, one study identified a
novel mechanism that regulates the activity of the membrane-
bound receptor for platelet-derived growth factor A (PDGFRα),
crucial for controlling the production of oligodendrocytes for
myelination (Pituch et al., 2015). This study tested whether
galactosylceramides (sulfatides) contribute to the regulation of
oligodendrogenesis by modulating PDGFRα function. It was
found that increased sulfatides levels in multipotential neural
precursors lead to a reduced production of oligodendrocytes
progenitor cells and oligodendrocytes. The activity of PDGFRα
depends on its localization to detergent-resistant membrane
domains in the plasma membrane and interaction with integrin
complexes and therefore, the diminished association of PDGFRα
with these domains due to increased sulfatides levels resulted
in exacerbated PDGFRα activity. This study identified a
novel mechanism that regulates the secretion of PDGFRα in
multipotential neural precursor cells, in glial cells, and in the
brain cortex via exosomal shedding. While the in vitro data
has shown that PDGFRα is secreted by multipotential neural
precursors and by glial cells via exosomes, the in vivo study
has shown that PDGFRα is secreted via exosomes during the
peak of myelination (Pituch et al., 2015). Exosomal PDGFRα
secretion may be a physiologically relevant function of exosomal
secretion by which oligodendrocytes progenitor cells rapidly and
locally regulate the concentration of the receptor. This can have
an impact on the receptor-mediated responses to proliferation,
survival and differentiation. Thus, the in vivo studies provide
further evidence that exosomal regulation of PDGFRα is part of
a larger regulatory program involved in myelination.
Alzheimer’s Disease
Extensive research has shown that several metabolites of the
APP are toxic to neuronal cells. A central pathological feature
of AD is the accumulation of Aβ in the brain, and it was
suggested that Aβ has an important role in the pathogenesis of
neuronal dysfunction in the disease (reviewed in Selkoe, 1991;
Hardy and Selkoe, 2002; Stine et al., 2003). Recent in vitro and
in vivo studies show that other APP metabolites, mainly the
β-secretase derived APP-CTFs, are neurotoxic and can cause
memory loss (Jiang et al., 2010; Deyts et al., 2012; Tamayev and
D’Adamio, 2012; Tamayev et al., 2012). Most significantly, it
was shown that APP-βCTF cause neuronal endosomal-lysosomal
abnormalities and resulting memory loss (Neve et al., 1996;
Oster-Granite et al., 1996; Neve and Robakis, 1998; McPhie et al.,
2001; Jiang et al., 2010; Deyts et al., 2012; Flammang et al.,
2012; Lauritzen et al., 2012, 2016; Oules et al., 2012; Tamayev
and D’Adamio, 2012; Tamayev et al., 2012). Exosomal proteins
were found to accumulate in the amyloid plaques in the brain
of AD patients (Rajendran et al., 2006) and therefore it was
proposed that exosomes participate in the pathogenesis of AD.
Exosomes isolated from the conditionedmedium of neuronal cell
cultures contain as cargo the full-length APP, APP metabolites,
and key enzymes that cleave both full-length APP and CTFs, and
exosomes are one site where APP processing occurs (Rajendran
et al., 2006; Vingtdeux et al., 2007; Escrevente et al., 2008; Sharples
et al., 2008). The presence of precursors to amyloidogenic
proteins and amyloidogenic proteins within exosomes suggest
that exosomes can release amyloidogenic material and transmit
it between cells, playing a pathogenic role in neurodegenerative
diseases.
Isolation of exosomes from mouse brains had shown that
murine brain exosomes contain full-length APP and the APP
metabolites APP-CTFs and Aβ (Perez-Gonzalez et al., 2012) as
was shown previously for exosomes isolated from the media
cultured by neuronal cells in vitro (Vingtdeux et al., 2007). A
novel finding was that exosomes isolated from brains of mice
are enriched with APP-CTFs compared to brain homogenates
(Perez-Gonzalez et al., 2012). These results imply the existence
of a set of mechanisms driving an enrichment of APP-CTFs
in exosomes. Additionally brain exosomes were isolated from
brains of transgenic mice overexpressing human APP with the
K670N/M671L Swedish double mutation (Tg2576; Hsiao et al.,
1996). The findings showed that the amount of flAPP and APP-
CTFs secreted out of the cell in brain exosomes is proportional
to their expression levels in the brain, but that the exosomes
are greatly enriched with APP-CTFs (Perez-Gonzalez et al.,
2012). Immuno-EM using antibodies directed to cytoplasmic or
extracellular epitopes of APP revealed that the exosomes are
oriented with the cytoplasmic-side facing inward (Pisitkun et al.,
2004). Therefore, cleavage of APP results in capture of APP-
CTFs inside exosomes. Thus, the enrichment of APP-CTFs in
exosomes isolated from brains results from endosomal APP-
CTFs that were captured and carried by exosomes combined with
metabolism of flAPP in the exosomes. Contrary to flAPP and
APP-CTFs, only a minute fraction of total Aβ (<1%) is associated
with exosomes (Rajendran et al., 2006). The orientation of APP
in the membrane of exosomes would result in the secretion of
exosomal-generated Aβ into the extracellular space, not into the
vesicles. Data suggest that Aβ binds to exosomes that possibly act
as a seed for plaque formation (reviewed in Dinkins et al., 2016a).
Isolation of exosomes from murine brain also enables
direct in vivo study of the effect of exosomes release on
amyloidogenesis. This was studied in a transgenic mouse
expressing five familial mutations in the human APP and
presenilin 1 genes (5XFAD). This model primarily produces
Aβ42, with amyloid plaques forming as early as at 3 months
of age (Oakley et al., 2006). Prevention of exosomes secretion
by the inhibition of neutral sphingomyelinase 2 (nSMase2), a
key regulatory enzyme generating ceramide from sphingomyelin,
with GW4869 in the 5XFAD transgenic mouse reduced
total Aβ42 levels and plaque load in the brain (Dinkins
et al., 2014). In genetically nSMase2-deficient 5XFAD mice,
reduced glial activation, total Aβ42 and plaque burden, and
tau phosphorylation, along with an improvement in a fear-
conditioned learning task were observed (Dinkins et al., 2016b).
These findings are consistent with the idea that APP metabolite
loaded exosomes may, under some conditions, contribute to
amyloidogenesis. Additionally, the isolation of exosomes from
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mouse brain facilitated the identification of a difference between
females and males, showing that the reduction of total Aβ42
levels and the number of plaques in the brain with a reduction in
nSMase2 function was significantly greater in male than female
mice (Dinkins et al., 2014), suggesting sex differences in brain
exosome secretion or function. This information may provide
a mechanism for the higher vulnerability of females to AD
pathogenesis: sex differences have been reported in AD, with
evidence that women expressing the apolipoprotein E4 allele have
a higher risk of being affected by AD than men, regardless of
longevity and other disease mortality factors (Payami et al., 1994;
Buckwalter et al., 1996; Farrer et al., 1997; Andersen et al., 1999;
Bretsky et al., 1999; Lobo et al., 2000; Mortensen and Hogh, 2001;
Brookmeyer et al., 2002; Barnes et al., 2003; Baum, 2005; Beydoun
et al., 2010; Altmann et al., 2014).
Another major hallmark of AD is the accumulation of
pathological tau protein, spreading in well-defined stages
between different regions of the brain, potentially via exosomes.
Exosomes-associated tau phosphorylated at Thr-181 (AT270), an
established phosphorylated tau biomarker for AD, was found in
tissue culture media and in human CSF samples, suggesting that
exosomes-mediated secretion of phosphorylated tau plays a role
in the abnormal processing of tau in early AD (Saman et al.,
2012). It was hypothesized thatmicroglia, the primary phagocytes
in the brain, facilitate tau protein propagation between neurons
by phagocytosing and exocytosing tau, supported by the finding
that depleting microglia dramatically suppressed the propagation
of tau (Asai et al., 2015). An in vitro study had shown that
microglia are more efficient at the uptake of tau as compared
to neurons and astrocytes. Isolation of exosomes from the
brain of a mouse model of tau propagation revealed that
vesicles that contain exosomal proteins contain tau and that
exosomes isolated from the brain of these mice transduce tau
into primary cultured neurons (Asai et al., 2015). Moreover,
microglial depletion partially reduced tau content in exosomes,
and inhibiting exosomes synthesis significantly reduced tau
propagation in vitro and in vivo. These data suggest that
exosomes may play a prominent role in the progression of
tauopathy within the brain (Asai et al., 2015).
A study that isolated exosomes from the brain of a tau
transgenic mouse that expresses four-repeat tau with the P301L
mutation showed that exosomes levels of tau were significantly
higher in transgenic mice that have pronounced tau pathology
(Polanco et al., 2016). Tau in the vesicles was differentially
phosphorylated, although to a lower degree than in the brain cells
from which they were derived. Several phospho-epitopes (AT8,
AT100, and AT180) thought to be critical for tau pathology were
undetected in brain exosomes. Despite this, exosomes derived
from transgenic mice were capable of seeding tau aggregation
in a threshold-dependent manner, demonstrating that tau-
containing exosomes can transmit tau pathology. Moreover, the
characteristics of tau in the exosomes and the high seeding
threshold identified may explain why tau pathology develops
very slowly in neurodegenerative diseases such as AD (Polanco
et al., 2016). In another study, the seeding potential of lysates
and EVs enriched for exosomes from wild-type and the tau
transgenic mouse brains was compared, showing that the
transgenic exosomes cause increased tau phosphorylation and
soluble oligomer formation in a manner comparable to that of
freely available proteins in brain lysates, a prerequisite for the
formation of mature protein aggregate (Baker et al., 2016). These
in vivo studies show that exosomes can propagate tau pathology,
can carry tau seeds able to induce tau aggregation in recipient
cells, and that such tau is phosphorylated at epitopes found in
AD patients.
Dementia with Lewy Body and Parkinson’s
Disease
α-synuclein aggregation plays a central role in Parkinson’s disease
pathology. Exosomes released from α-synuclein overexpressing
SH-SY5Y cells contain α-synuclein, and these exosomes were
capable of efficiently transferring α-synuclein to normal SH-
SY5Y cells (Emmanouilidou et al., 2010; Alvarez-Erviti et al.,
2011). An in vitro study that examined the role of the ESCRT
pathway in the propagation of α-synuclein has shown that
disruption of the ESCRT transport system resulted in increased
exocytosis of α-synuclein (Spencer et al., 2016). The in vitro study
also showed that the ESCRT protein-charged multivesicular
body protein (CHMP2B) affects the release of α-synuclein, and
downregulation of CHMP2B affects the intracellular capacity
of cells to clear α-synuclein, leading to greater release of α-
synuclein into the media. Consistent with these findings, lower
levels of CHMP2B were found in the brain of patients diagnosed
with dementia with Lewy body as compared with controls,
thus generating a roadblock of endocytosed α-synuclein. In
order to determine whether α-synuclein is released via exosomes
in vivo, exosomes were isolated from brain of patients with
dementia with Lewy body, revealing that the exosomes contained
α-synuclein, while exosomes isolated from control individuals
did not (Spencer et al., 2016). These data suggest that
neurons compensate for dysfunction of the endosomal-lysosomal
pathway that cause accumulation of material such as α-synuclein
in MVB by enhanced release of exosomes, potentially increasing
cell-to-cell propagation of α-synuclein in neurological disorders
with parkinsonism, including Parkinson’s disease and dementia
with Lewy body.
Amyotrophic Lateral Sclerosis and
Frontotemporal Lobar Degeneration
Similar to dementia with Lewy body, data on exosomes-
associated TDP-43, a pathological hallmark of amyotrophic
lateral sclerosis and frontotemporal lobar degeneration, suggest
that enhanced exosomes release is beneficial to neuronal survival,
in spite of potential increase in disease propagation (Iguchi
et al., 2016). in vitro investigation of the role of exosomes in
the secretion and propagation of TDP-43 aggregates have shown
that TDP-43 is secreted by neurons but not by astrocytes or
microglia in association with exosomes. Isolation of exosomes
from human brains had shown that levels of exosomal TDP-43
full length and C-terminal fragment species are upregulated in
human amyotrophic lateral sclerosis brains. When Neuro2a cells
were exposed to exosomes from amyotrophic lateral sclerosis
brain, but not from control brain, cytoplasmic redistribution of
TDP-43 was observed (Iguchi et al., 2016). These data suggest
that secreted exosomes contribute to propagation of TDP-
43 proteinopathy. However, inhibition of exosomes secretion
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provoked formation of TDP-43 aggregates in Neuro2a cells
and exacerbated TDP-43 neuronal aggregation. Moreover, the
disease phenotypes of transgenic mice expressing human TDP-
43A315T mutant was exacerbated following in vivo inhibition of
exosomes secretion. Given that cytoplasmic TDP-43 aggregation
occurs in amyotrophic lateral sclerosis and frontotemporal lobar
degeneration, these results suggest that exosomes containing
pathological TDP-43 play a role in the propagation of TDP-
43 proteinopathy. Thus, a therapeutic strategy for amyotrophic
lateral sclerosis based on inhibition of exosomes production
based on in vivo data that suggest that exosomes secretion plays
an overall beneficial role in neuronal clearance of pathological
TDP-43 would be inadvisable (Iguchi et al., 2016).
Simian Immunodeficiency Virus-Induced
Brain Disease
Investigation of the role of exosomes in simian
immunodeficiency virus (SIV)-induced brain disease was
conducted by the isolation and characterization of exosomes
from the brains of rhesus macaques. Small RNA sequencing
revealed higher miR-21 levels in exosomes from SIV encephalitic
brains compared with controls (Yelamanchili et al., 2015a,b).
In situ hybridization revealed increased miR-21 expression in
neurons and macrophage/microglial cells/nodules during SIV
induced brain disease. in vitro culture of macrophages have
shown that miR-21 is released via exosomes and is neurotoxic via
activation of TLR7 when compared to exosomes derived from
miR-21 knockout mice (Yelamanchili et al., 2015a,b). This study
further emphasizes the value of the characterization of exosomal
response in the affected brain in combination with an in vitro
study to further define the mechanism of action.
Traumatic Brain Injury
The same exosomes-associated miRNA involved in SIV-induced
brain disease was found to have a role in traumatic brain injury
(TBI; Harrison et al., 2016). While several experiments have
shown the effects of exosomes-associated miRNA on cells in
culture, this study investigated how miRNA content of exosomes
is altered in vivo in the brain. Exosomes were isolated from the
brain of a mouse model of TBI (controlled cortical impact) and
controls. Profiling of miRNA in the exosomes has shown changes
in miRNA species, with miR-21 showing the largest change
between conditions. Highlighting the value of isolating exosomes
from the brain directly, the miRNA profiles found in this study
were not identical to those seen in exosomes isolated from human
CSF after TBI described in a previous study (Patz et al., 2013).
It remains to be determined whether the difference between
the studies is due solely to a difference between CSF and brain
exosomes, or due to a difference between TBI in humans and
the mouse model, critical to the interpretation of further studies.
Study of the mouse brain has shown that the expression of miR-
21 in the brain was primarily localized to neurons, not microglia,
near the lesion site, while adjacent to these miR-21-expressing
neurons were activated microglia. The concurrent elevation of
miR-21 in neurons with the increase in miR-21 in exosomes
suggests that miR-21 secreted from neurons in association with
exosomes is a potential mechanism of cell-to-cell communication
resulting in microglia activation as a protective mechanism.
Thus, while a neurotoxic function of exosomes-associated miR-
21 was shown in the brain of SIV-induced rhesus macaques brain
disease (Yelamanchili et al., 2015a,b), a protective function is
suggested, but needs to be proven, in a mouse model of TBI
(Harrison et al., 2016).
Schizophrenia and Bipolar Disorder
In another study, well-preserved exosomal miRNAs were isolated
from frozen postmortem prefrontal cortices and submitted to
RNA profiling to examine whether they reflect disease-specific
changes in psychiatric disorders (Banigan et al., 2013). The
expression of certain exosomal miRNA in the brains of patients
diagnosed with schizophrenia and bipolar disorder differed
from controls, reflecting either disease-specific or common
aberrations in these patients. RT-PCR validation confirmed that
two miRNAs, miR-497 in schizophrenia brain samples and miR-
29c in bipolar disorder brain samples, have significantly higher
expression when compared to control samples (Banigan et al.,
2013). These results show that brain exosomes characterization
has the potential to identify the cellular mechanism of disease
pathology, as well as showing the potential of exosomes-derived
miRNAs to serve as biomarkers for various disorders.
CONCLUSIONS
Studies of exosomes isolated from brain tissue demonstrate that
unique, brain-specific data can be obtained, findings that are
not available from exosomes isolated from conditioned media
or body fluids. Moreover, they show that exosomes released
into the extracellular space of human and mouse brains under
disease conditions have different exosomal cargo proteins and
miRNAs compared with unaffected controls. However, these
in vivo studies are not able to identify specific cellular sources of
these exosomes as well as cell biological and vesicle trafficking
alterations that alter exosomes, data that can be obtained from
cultured cells. Given that brain-derived exosomes can reflect
disease processes, they may also be used to evaluate the effect of
therapeutic interventions on specific markers.
As the field continues to undertake a comprehensive and
integrated analysis of brain tissue exosomes, exosomes secreted
from the various cell-types found within the brain, and from the
CSF, our understanding of exosomes secretion as a cellular rescue
pathway and as a potential mechanisms for disease propagation
will grow. Additionally, the newly appreciated value of exosomes
as biomarkers for disease diagnosis and informers of pathogenic
processes within cells will likely lead to greater use of exosomal
analyses as translation research and clinical tools.
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